Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | ADH1C | P00326 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.36 |
| ▸ | ADH4 | P08319 | 1/20 | 0.36 |
| ▸ | ADH7 | P40394 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575542 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AADH1B | |
| SCHEMBL1410668 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AADH1B | |
| SCHEMBL15326958 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AADH1B | |
| SCHEMBL23803614 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AADH1B | |
| SCHEMBL15326984 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AADH1B | |
| SCHEMBL23803613 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AADH1B | |
| SCHEMBL294760 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AADH1B | |
| SCHEMBL23803605 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AADH1B | |
| SCHEMBL15326982 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AADH1B | |
| SCHEMBL15873759 | 1.00 | TSHR (0.52) | TSHRFAAHTRPV1HIF1AADH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113582821-B | Preparation method of 8-methyldecanal | 泛亚（武汉）食品科技有限公司 | 2024-02-27 | — | — | CN | claimed |
| US-11548846-B2 | Method of preparing 8-methyldecanal | Panasia (Wuhan) Food Science Technology Co., Ltd (CN) | 2023-01-10 | — | — | US | claimed |
| US-20220127214-A1 | Method of Preparing 8-Methyldecanal | Panasia (Wuhan) Food Science Technology Co., Ltd (CN) | 2022-04-28 | — | — | US | claimed |
| CN-113582821-A | Preparation method of 8-methyl decanal | 泛亚（武汉）食品科技有限公司 | 2021-11-02 | — | — | CN | claimed |
| US-10294275-B2 | Site-selective functionalization of glycopeptide antibiotics | YALE UNIVERSITY (US) | 2019-05-21 | — | — | US | claimed |
| US-20160039881-A1 | SITE-SELECTIVE FUNCTIONALIZATION OF GLYCOPEPTIDE ANTIBIOTICS | YALE UNIVERSITY (US) | 2016-02-11 | — | — | US | claimed |
| WO-2014160250-A9 | SITE-SELECTIVE FUNCTIONALIZATION OF GLYCOPEPTIDE ANTIBIOTICS | YALE UNIVERSITY (US) | 2015-12-17 | — | — | WO | claimed |
| WO-2014160250-A2 | SITE-SELECTIVE FUNCTIONALIZATION OF GLYCOPEPTIDE ANTIBIOTICS | YALE UNIVERSITY (US) | 2014-10-02 | — | — | WO | claimed |
| US-7335725-B2 | Lipopeptides as antibacterial agents | CUBIST PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | claimed |
| US-5936074-A | REACTING TEICOPLANIN WITH ECHINOCANDIN BETA DEACYLASE, THEN FORMING SALT AND/OR DEPROTECTING AMINO GROUP; BACTERICIDES AGAINST GRAM-POSITIVE BACTERIA | ELI LILLY AND COMPANY (US) | 1999-08-10 | — | — | US | claimed |
| EP-0095295-B1 | CYCLIC PEPTIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1987-01-14 | — | — | EP | claimed |
| US-RE32311-E | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1986-12-16 | — | — | US | claimed |
| US-4537717-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1985-08-27 | — | — | US | claimed |
| US-4482487-A | A-21978C cyclic peptides | ELI LILLY AND COMPANY (US) | 1984-11-13 | — | — | US | claimed |
| EP-0095295-A1 | Cyclic peptide derivatives | ELI LILLY AND COMPANY (US) | 1983-11-30 | — | — | EP | claimed |
| US-RE31396-E | A-21978 Antibiotics and process for their production | ELI LILLY AND COMPANY (US) | 1983-09-27 | — | — | US | claimed |
| US-4396543-A | Derivatives of A-21978C cyclic peptides | ELI LILLY AND COMPANY (US) | 1983-08-02 | — | — | US | claimed |
| US-4331594-A | PEPTIDE ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1982-05-25 | — | — | US | claimed |
| US-4208403-A | A-21978 Antibiotics and process for their production | ELI LILLY AND COMPANY (US) | 1980-06-17 | — | — | US | claimed |
| EP-0010421-A1 | Mixture of antibiotics designated by A-21978, process for its production, their pharmaceutical compositions and producing microorganism | ELI LILLY AND COMPANY (US) | 1980-04-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039881-A1 | SITE-SELECTIVE FUNCTIONALIZATION OF GLYCOPEPTIDE ANTIBIOTICS | CUTA, VIP, GNE | TSHR 2746/4885FAAH 3269/4885TRPV1 1147/4885 |
| US-10294275-B2 | Site-selective functionalization of glycopeptide antibiotics | CUTA, VIP, GNE | TSHR 2746/4885FAAH 3269/4885TRPV1 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.